Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...
Polymer-based gene delivery systems represent a promising class of non-viral vectors, offering significant advantages in safety, structural versatility, biodegradability, and the potential for ...
Spun out of MIT, the company is engineering a new class of biomolecules at 10x lower cost and drastically increased scale to advance gene editing toward cures for complex diseases. “We believe curing ...
Advanced Gene Therapy Development Solutions: A Comprehensive Platform for Next-Generation Therapeutic Innovation: The landscape of gene therapy has evolved dramatically over the past decade, ...
Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay Capital New Investment, Combined with Recent $8.4 Million ARPA-H Award, Brings Funds ...
Gene transfer is seen as a hopeful therapy for Alzheimer's and Parkinson's patients. The approach involves using harmless laboratory-produced viruses to introduce important genes into the brain cells.
Macromolecular-based gene delivery systems have emerged as viable alternatives to non-viral vectors for gene therapy due to their versatility, biocompatibility, and capacity to efficiently deliver ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kano Therapeutics, a biotechnology company pioneering single-stranded DNA (ssDNA) as a safe, efficient and flexible biomolecule for gene insertions, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results